SureTrader
Home > Boards > US OTC > Medical - Drugs >

AVAX TECHNOLOGIES INC (AVXT)

AVXT RSS Feed
Add AVXT Price Alert      Hide Sticky   Hide Intro
Moderator: johnny canuck
Search This Board:
Last Post: 8/26/2016 12:49:51 PM - Followers: 32 - Board type: Free - Posts Today: 0

 

Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
CEO: Adele Sommerfeld
BOD: Andrew W. Dahl Sc.D.; Serge Morrell
 
 
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

 


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


 

Press Releases & AVAX Information:

https://en.wikipedia.org/wiki/Avax_Technologies

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551891/

http://www.ncbi.nlm.nih.gov/pubmed/22854662

http://www.clinicaltrials.gov/ct2/show/NCT00477906?term=MVax&rank=1

http://clinicaltrials.gov/show/NCT00660101

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20130309271&OS=20130309271&RS=20130309271

http://www.biotechblog.org/Tags/cancer-treatment-centers-of-america/

http://www.thefreelibrary.com/AVAX+Technologies+Announces+Collaboration+with+Cancer+Treatment...-a0159564876

http://www.reuters.com/article/2014/01/08/ctca-trial-cancer-idUSnPnDChVKwJ+16d+PRN20140108

http://ih.advfn.com/p.php?pid=nmona&article=61013370

http://www.bizjournals.com/philadelphia/blog/health-care/2014/02/ovarian-cancer-vaccine-testing-expands.html

http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing

 
By

Published: Aug 4, 2015 7:31 p.m. ET

Share
 
 
 
 

PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.


AVAX TECHNOLOGIES WEBSITE IS NOW ACTIVE:    WWW.AVAX-TECH.COM/
 

AVAX TECHNOLOGIES, INC APPOINTS NEW CEO: ADELE SOMMERFELD 10/19/2015
http://www.prnewswire.com/news-releases/avax-technologies-inc-announces-the-appointment-of-chief-executive-officer-300161646.html



 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#1342  Sticky Note http://www.prnewswire.com/news-releases/avax-technologies-announces-results-of-i johnny canuck 01/26/16 07:32:21 PM
#1456   I do not believe anyone is in the Geoman1 08/26/16 12:49:51 PM
#1455   sorry sir, so many of us in the akika 08/26/16 01:15:10 AM
#1454   100 G's to now 2.4 G's. These people Geoman1 08/25/16 09:30:53 PM
#1453   Hello, anybody home>??? akika 08/20/16 08:53:05 PM
#1452   please turn the lights off when you are done. akika 08/17/16 11:51:35 PM
#1451   This thing isn't getting too manipulated........nooooooo. johnny canuck 08/17/16 07:29:13 PM
#1450   sad, I guess everyone zapped. akika 08/12/16 03:36:11 PM
#1449   are you still here? akika 08/11/16 08:39:07 PM
#1448   I think the circus left town with the johnny canuck 07/30/16 08:54:37 PM
#1447   What a freakin AVXT circus today Geoman1 07/21/16 03:17:30 PM
#1446   My rationale is right now, I do not Geoman1 07/20/16 10:27:14 AM
#1445   http://www.consumereagle.com/avax-techs-incorporated-otcmktsavxt-shorts-decrease katter 07/19/16 11:45:47 PM
#1444   Sir, are you still here? how many shares akika 07/19/16 10:24:31 PM
#1443   I would forget penny stocks, buy good stocks katter 07/19/16 08:23:46 PM
#1442   Thanks, its 1959 Thats TurningPoint 07/18/16 01:13:46 PM
#1441   Why don't you ask us all? He or katter 07/18/16 01:06:36 PM
#1440   How are you sir? Sorry for your TurningPoint 07/17/16 08:51:32 PM
#1439   Did you try calling Mrs. Sommerfeld? This is medimpact 07/15/16 01:16:30 PM
#1438   sorry about everything sir, I wish you better akika 07/12/16 09:29:02 PM
#1437   I am not grateful. I am disgusted. I Geoman1 07/11/16 06:47:32 PM
#1436   Be grateful sir, 3.2 is better than nothing. akika 07/11/16 04:11:39 PM
#1435   In flames...100G's to 3.2 G's. This is a Geoman1 07/11/16 01:35:34 PM
#1434   I'm sorry, I cannot figure out who is tencoin 07/04/16 09:23:05 AM
#1433   Well Goosey, johnny canuck 07/03/16 08:24:40 PM
#1432   Thanks JC, I appreciate your investigation. Keep the faith. Goosey 07/03/16 07:06:05 PM
#1431   Looks like "that Baird" is a research/fund mgt. johnny canuck 07/03/16 12:20:13 PM
#1430   I am having a difficult time connecting Robert Goosey 07/03/16 11:58:13 AM
#1429   http://finance.yahoo.com/mb/AVXT/ googling around... katter 07/02/16 02:04:12 PM
#1428   http://www.americanbankingnews.com/2016/06/27/sarepta-therapeutics-inc-srpt-stock-rating-reaffirmed- katter 07/02/16 01:58:45 PM
#1427   Link ... please! tencoin 07/02/16 02:04:19 AM
#1426   Interesting...Baird doing work with Sarepta Therapeutics.....guy gets around.... Geoman1 07/02/16 12:56:54 AM
#1425   Interesting...Baird doing work with Sarepta Therapeutics.....guy gets around.... Geoman1 07/02/16 12:56:47 AM
#1424   Interesting...Baird doing work with Sarepta Therapeutics.....guy gets around.... Geoman1 07/02/16 12:56:37 AM
#1423   Minus 94% as of today. Rippin the guts Geoman1 06/23/16 05:58:45 PM
#1422   Apparently she left in May and they did Geoman1 06/22/16 03:13:54 PM
#1421   Unreal! Sommerfeld gone after only 9 months. Where Geoman1 06/22/16 12:22:18 PM
#1420   I have a bundle into this too and coco for cocoa puffs 06/21/16 12:13:54 PM
#1419   Yep, now down 93.2%. Be positive even if Geoman1 06/20/16 11:07:34 AM
#1418   quote: http://nextgenpersonalfinance.org/question-of-the-day-what-does-a-ceo-do- katter 06/17/16 05:01:34 PM
#1417   Weren't they supposed to raise $45 millions by medimpact 06/16/16 12:58:08 PM
#1416   Do you really believe that all the people katter 06/15/16 03:08:15 PM
#1415   Enjoy your retirement, be glad you made it katter 06/15/16 03:07:42 PM
#1414   i GOOGLED to try to help you geoman, katter 06/14/16 04:57:25 PM
#1413   At market close today I am now down Geoman1 06/13/16 04:33:13 PM
#1412   Just wonderful. 86.5% loss as of today on Geoman1 06/06/16 12:07:25 PM
#1411   Yeah, go baby....look where it is today! My Geoman1 05/26/16 01:58:58 PM
#1410   Go baby, go baby, go baby!!!!!!! :) johnny canuck 05/10/16 07:13:05 PM
#1409   WOW! I'm surprised. johnny canuck 05/03/16 05:40:25 PM
#1408   Could be MM head games. Waiting for EOD johnny canuck 05/03/16 02:28:23 PM
#1407   These people are driving this stock and company Geoman1 05/02/16 07:56:39 PM
PostSubject